Wnt/β-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): A target for current and potential therapeutic options

Current Cancer Drug Targets

Volumn 10, Issue 7, 2010, Pages 716-727

  Gandhirajan, R K ^a   Poll Wolbeck, S J ^a   Gehrke, I ^a   Kreuzer, K A ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chronic lymphocytic leukemia; Targeted therapy; Wnt signaling

Indexed keywords

2,4 DIAMINO QUINAZOLINE; ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BETA CATENIN; CGP 049090; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETACRYNIC ACID; FLUDARABINE; FRIZZLED PROTEIN; ICG 001; LYMPHOID ENHANCER FACTOR 1; NICLOSAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OBLIMERSEN; PENTOSTATIN; QUERCETIN; QUINAZOLINE DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 78649302763     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910793605794     Document Type: Article

References (120)

1. Meinhardt, G.; Wendtner, C. M.; Hallek, M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J. Mol. Med. 1999, 77, 282-293.
2. Keating, M. J.; Kantarjian, H.; OBrien, S.; Koller, C.; Talpaz, M.; Schachner, J.; Childs, C. C.; Freireich, E. J.; Mccredie, K. B. Fludarabine - a new agent with marked cytoreductive activity in untreated chronic lymphocytic-leukemia. J. Clin. Oncol. 1991, 9, 44-49.
3. Rai, K. R.; Peterson, B. L.; Appelbaum, F. R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threatte, G. A.; Larson, R. A.; Cheson, B. D.; Schiffer, C. A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 2000, 343, 1750-1757.
4. Johnson, S.; Catovsky, D.; Child, J.; Newland, A. C.; Milligan, D.; Janmohamed, R. Phase I/II evaluation of 2' deoxycoformycin (Pentostatin) in a five-day schedule for the treatment of relapse/refractory chronic lymphocytic leukaemia (CLL). Blood 1996,88, 2350-2350.
5. Keating, M. J.; O'Brien, S.; Lerner, S.; Koller, C.; Beran, M.; Robertson, L. E.; Freireich, E. J.; Estey, E.; Kantarjian, H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998, 92, 1165-1171.
6. Leporrier, M.; Chevret, S.; Cazin, B.; Boudjerra, N.; Feugier, P.; Desablens, B.; Rapp, M. J.; Jaubert, J.; Autrand, C.; Divine, M.; Dreyfus, B.; Maloum, K.; Travade, P.; Dighiero, G.; Binet, J. L.; Chastang, C. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98, 2319-2325.
7. Hallek, M.; Schmitt, B.; Wilhelm, M.; Busch, R.; Krober, A.; Fostitsch, H. P.; Sezer, O.; Herold, M.; Knauf, W.; Wendtner, C. M.; Kuse, R.; Freund, M.; Franke, A.; Schriever, F.; Nerl, C.; Dohner, H.; Thiel, E.; Hiddemann, W.; Brittinger, G.; Emmerich, B. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia, (CLL): results of a phase II study of the German CLL Study Group. Br. J. Haematol. 2001, 114, 342-348.
8. Eichhorst, B.; Hallek, M. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). Best Pract. Res. Clin. Haematol. 2007, 20, 469-477.
9. Robak, T. The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials. Leuk. Lymphoma 2002, 43, 537-548.
10. Montillo, M.; Tedeschi, A.; O'Brien, S.; Di Raimondo, F.; Lerner, S.; Ferrajoli, A.; Morra, E.; Keating, M. J. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003, 97, 114-120.
11. Del Poeta, G.; Del Principe, M. I.; Buccisano, F.; Maurillo, L.; Capelli, G.; Luciano, F.; Perrotti, A. P.; Degan, M.; Venditti, A.; de Fabritiis, P.; Gattei, V.; Amadori, S. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008, 112, 119-128.
12. Robak, T.; Smolewski, P.; Cebula, B.; Szmigielska-Kaplon, A.; Chojnowski, K.; Blonski, J. Z. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006, 107, 1542-1550.
13. Tam, C. S.; Keating, M. J. Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract. Res. Clin. Haematol. 2007, 20, 479-498.
14. Voso, M. T.; Pantel, G.; Rutella, S.; Weis, M.; D'Alo, F.; Urbano, R.; Leone, G.; Haas, R.; Hohaus, S. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002, 87, 918-925.
15. Byrd, J. C.; Murphy, T.; Howard, R. S.; Lucas, M. S.; Goodrich, A.; Park, K.; Pearson, M.; Waselenko, J. K.; Ling, G.; Grever, M. R.; Grillo-Lopez, A. J.; Rosenberg, J.; Kunkel, L.; Flinn, I. W. Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 2001,19, 2153-2164.
16. Itala, M.; Geisler, C. H.; Kimby, E.; Juvonen, E.; Tjonnfjord, G.; Karlsson, K.; Remes, K. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur. J. Haematol. 2002, 69, 129-134.
17. O'Brien, S. M.; Kantarjian, H.; Thomas, D. A.; Giles, F. J.; Freireich, E. J.; Cortes, J.; Lerner, S.; Keating, M. J. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 2001, 19, 2165-2170.
18. Byrd, J. C.; Rai, K.; Larson, R. A. Response: Rituximab and fludarabine combination therapy for CLL: potential future directions of clinical investigation. Blood 2003, 102, 2309-2310.
19. Schulz, H.; Klein, S. K.; Rehwald, U.; Reiser, M.; Hinke, A.; Knauf, W. U.; Aulitzky, W. E.; Hensel, M.; Herold, M.; Huhn, D.; Hallek, M.; Diehl, V.; Engert, A. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002, 100, 3115-3120.
20. Keating, M. J.; O'Brien, S.; Lerner, S.; Wierda, W.; Kantarjian, H. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and ritux-imab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL). J. Clin. Oncol. 2004, 22, 573S-573S.
21. Wierda, W.; O'Brien, S.; Wen, S.; Faderl, S.; Garcia-Manero, G.; Thomas, D.; Do, K. A.; Cortes, J.; Koller, C.; Beran, M.; Ferrajoli, A.; Giles, F.; Lerner, S.; Albitar, M.; Kantarjian, H.; Keating, M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2005, 23, 4070-4078.
22. Keating, M. J.; O'Brien, S.; Kontoyiannis, D.; Plunkett, W.; Koller, C.; Beran, A.; Lerner, S.; Kantarjian, H. Results of first salvage therapy for patients refractory to a fluidarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma 2002, 43, 1755-1762.
23. Osterborg, A.; Mellstedt, H.; Keating, M. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med. Oncol. 2002, 19, S21-S26.
24. Rai, K. R.; Freter, C. E.; Mercier, R. J.; Cooper, M. R.; Mitchell, B. S.; Stadtmauer, E. A.; Santabarbara, P.; Wacker, B.; Brettman, L. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 2002, 20, 3891-3897.
25. Lozanski, G.; Heerema, N. A.; Flinn, I. W.; Smith, L.; Harbison, J.; Webb, J.; Moran, M.; Lucas, M.; Lin, T.; Hackbarth, M. L.; Proffitt, J. H.; Lucas, D.; Grever, M. R.; Byrd, J. C. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103, 3278-3281.
26. Stilgenbauer, S.; Scherer, K.; Krober, A.; Bullinger, L.; Hochsmann, B.; Mayer-Steinacker, R.; Bunjes, D.; Dohner, H. Campath-1H in refractory B-CLL - Complete remission despite p53 gene mutation. Blood 2001, 98, 771A-771A.
27. Dreger, P.; Corradini, P.; Kimby, E.; Michallet, M.; Milligan, D.; Schetelig, J.; Wiktor-Jedrzejczak, W.; Niederwieser, D.; Hallek, M.; Montserrat, E. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21, 12-17.
28. Jabbour, E.; Keating, M. J.; Champlin, R. E.; Khouri, I. F. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant? Bone Marrow Transplant. 2004, 34, 289-297.
29. O'Brien, S. M.; Cunningham, C. C.; Golenkov, A. K.; Turkina, A. G.; Novick, S. C.; Rai, K. R. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol. 2005, 23, 7697-7702.
30. O'Brien, S.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A. A.; Seymour, J. F.; Bociek, R. G.; Pavletic, S.; Rai, K. R. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2007, 25, 1114-1120.
31. O'Connor, O.; Czuczman, M. S.; LaCasce, A.; Gerecitano, J.; Leonard, J. P.; Dunleavy, K.; Krivoshik, A.; Shovlin, M.; Narwal, A.; Xiong, H.; Chiu, Y.; Wilson, W. A phase 1 study evaluating the safety, PK & efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Ann. Oncol. 2008, 19, 115-116.
32. Kuhl, M.; Sheldahl, L. C.; Park, M.; Miller, J. R.; Moon, R. T. The Wnt/Ca2+ pathway - a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 2000, 16, 279-283.
33. Wang, H. Y.; Malbon, C. C. Wnt signaling, Ca2+, and cyclic GMP: Visualizing frizzled functions. Science 2003, 300, 1529-1530.
34. Weber, U.; Paricio, N.; Mlodzik, M. Jun mediates Frizzled-induced R3/R4 cell fate distinction and planar polarity determination in the Drosophila eye. Development 2000, 127, 3619-3629.
35. Tree, D. R. P.; Ma, D. L.; Axelrod, J. D. A three-tiered mechanism for regulation of planar cell polarity. Semin. Cell Dev. Biol. 2002, 13, 217-224.
36. Slusarski, D. C.; YangSnyder, J.; Busa, W. B.; Moon, R. T. Modulation of embryonic intracellular Ca2+ signaling by Wnt-5A. Dev. Biol. 1997, 182, 114-120.
37. Ahumada, A.; Slusarski, D. C.; Liu, X. X.; Moon, R. T.; Malbon, C. C.; Wang, H. Y. Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP. Science 2002, 298, 2006-2010.
38. Okamura, R. M.; Sigvardsson, M.; Galceran, J.; Verbeek, S.; Clevers, H.; Grosschedl, R. Redundant regulation of T cell differentiation and TCR alpha gene expression by the transcription factors LEF-1 and TCF-1. Immunity 1998, 8, 11-20.
39. Reya, T.; O'Riordan, M.; Okamura, R.; Devaney, E.; Willert, K.; Nusse, R.; Grosschedl, R. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000,13, 15-24.
40. Reya, T.; Duncan, A. W.; Ailles, L.; Domen, J.; Scherer, D. C.; Willert, K.; Hintz, L.; Nusse, R.; Weissman, I. L. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003,423, 409-414.
41. Kimelman, D.; Xu, W. beta-Catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006, 25, 7482-7491.
42. Ikeda, S.; Kishida, S.; Yamamoto, H.; Murai, H.; Koyama, S.; Kikuchi, A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3 beta and beta-catenin and promotes GSK-3 beta-dependent phosphorylation of beta-catenin. EMBO J. 1998, 17, 1371-1384.
43. Jiang, J.; Struhl, G. Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. Nature 1998, 391, 493-496.
44. Marikawa, Y.; Elinson, R. P. beta-TrCP is a negative regulator of the Wnt/beta-catenin signaling pathway and dorsal axis formation in Xenopus embryos. Mech. Dev. 1998, 77, 75-80.
45. Noordermeer, J.; Klingensmith, J.; Perrimon, N.; Nusse, R. Dishevelled and Armadillo Act in the Wingless Signaling Pathway in Drosophila. Nature 1994, 367, 80-83.
46. Kishida, M.; Koyama, S.; Kishida, S.; Matsubara, K.; Nakashima, S.; Higano, K.; Takada, R.; Takada, S.; Kikuchi, A. Axin prevents Wnt-3a-induced accumulation of beta-catenin. Oncogene 1999, 18, 979-985.
47. Smalley, M. J.; Sara, E.; Paterson, H.; Naylor, S.; Cook, D.; Jayatilake, H.; Fryer, L. G.; Hutchinson, L.; Fry, M. J.; Dale, T. C. Interaction of Axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J. 1999, 18, 2823-2835.
48. Itoh, K.; Antipova, A.; Ratcliffe, M. J.; Sokol, S. Interaction of dishevelled and Xenopus axin-related protein is required for Wnt signal transduction. Mol. Cell. Biol. 2000, 20, 2228-2238.
49. Hsu, S. C.; Galceran, J.; Grosschedl, R. Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin. Mol. Cell. Biol. 1998, 18, 4807-4818.
50. Nelson, W. J. and Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303, 1483-1487.
51. Moon, R. T.; Kohn, A. D.; De Ferrari, G. V.; Kaykas, A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 2004,5, 691-701.
52. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14, 1837-1851.
53. Giles, R. H.; van Es, J. H.; Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 2003, 1653, 1-24.
54. Lustig, B. and Behrens, J. The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol. 2003, 129, 199-221.
55. Morin, P. J.; Weeraratna, A. T. Wnt signaling in human cancer. Cancer Treat. Res. 2003, 115, 169-187.
56. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127, 469-480.
57. Gehrke, I.; Gandhirajan, R. K.; Kreuzer, K. A. Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options. Eur. J. Cancer 2009, 45, 2759-2767.
58. Gunther, E. J.; Moody, S. E.; Belka, G. K.; Hahn, K. T.; Innocent, N.; Dugan, K. D.; Cardiff, R. D.; Chodosh, L. A. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 2003, 17, 488-501.
59. Lane, T. F. and Philip, L. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 1997, 15, 2133-2144.
60. Huguet, E. L.; Mcmahon, J. A.; Mcmahon, A. P.; Bicknell, R.; Harris, A. L. Differential expression of human Wnt gene-2, gene-3, gene-4, and gene-7B in human breast cell-lines and normal and disease states of human breast-tissue. Cancer Res. 1994, 54, 2615-2621.
61. Smalley, M. J.; Dale, T. C. Wnt signaling and mammary tumorigenesis. J. Mammary Gland Biol. Neoplasia 2001, 6, 37-52.
62. Howe, L. R.; Brown, A. M. C. Wnt signaling and breast cancer. Cancer Biol. Ther. 2004, 3, 36-41.
63. Chen, S. Q.; Guttridge, D. C.; You, Z. B.; Zhang, Z. C.; Fribley, A.; Mayo, M. W.; Kitajewski, J.; Wang, C. Y. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J. Cell Biol. 2001, 152, 87-96.
64. You, L.; He, B.; Xu, Z.; Uematsu, K.; Mazieres, J.; Mikami, I.; Reguart, N.; McComick, F.; Jablons, D. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Lung Cancer 2005, 49, S76-S77.
65. You, L.; He, B.; Xu, Z. D.; Uematsu, K.; Mazieres, J.; Fujii, N.; Mikami, I.; Reguart, N.; McIntosh, J. K.; Kashani-Sabet, M.; McCormick, F.; Jablons, D. M. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 2004, 64, 5385-5389.
66. Simon, M.; Grandage, V. L.; Linch, D. C.; Khwaja, A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005, 24, 2410-2420.
67. Sukhdeo, K.; Mani, M.; Zhang, Y.; Dutta, J.; Yasui, H.; Rooney, M. D.; Carrasco, D. E.; Zheng, M.; He, H.; Tai, Y. T.; Mitsiades, C.; Anderson, K. C.; Carrasco, D. R. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc. Natl. Acad. Sci. USA 2007, 104, 7516-7521.
68. Rosenwald, A.; Alizadeh, A. A.; Widhopf, G.; Simon, R.; Davis, R. E.; Yu, X.; Yang, L. M.; Pickeral, O. K.; Rassenti, L. Z.; Powell, J.; Botstein, D.; Byrd, J. C.; Grever, M. R.; Cheson, B. D.; Chiorazzi, N.; Wilson, W. H.; Kipps, T. J.; Brown, P. O.; Staudt, L. M. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 2001,194, 1639-1647.
69. Saldanha, J.; Singh, J.; Mahadevan, D. Identification of a Frizzled-like cysteine rich domain in the extracellular region of developmental receptor tyrosine kinases. Protein Sci. 1998, 7, 1632-1635.
70. Fukuda, T.; Chen, L.; Endo, T.; Tang, L.; Lu, D.; Castro, J. E.; Widhopf, G. F.; Rassenti, L. Z.; Cantwell, M. J.; Prussak, C. E.; Carson, D. A.; Kipps, T. J. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal,antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. USA 2008,105, 3047-3052.
71. Lu, D.; Zhao, Y.; Tawatao, R.; Cottam, H. B.; Sen, M.; Leoni, L. M.; Kipps, T. J.; Corr, M.; Carson, D. A. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 2004, 101, 3118-3123.
72. Wodarz, A.; Nusse, R. Mechanisms of Wnt signaling in development. Ann. Rev. Cell Dev. Biol. 1998, 14, 59-88.
73. Wu, Q. L.; Zierold, C.; Ranheim, E. A. Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia. Blood 2009, 113, 3031-3039.
74. Golan, T.; Yaniv, A.; Bafico, A.; Liu, G. Z.; Gazit, A. The human frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt center dot beta-Catenin signaling cascade. J. Biol. Chem. 2004, 279, 14879-14888.
75. Tamai, K.; Semenov, M.; Kato, Y.; Spokony, R.; Liu, C. M.; Katsuyama, Y.; Hess, F.; Saint-Jeannet, J. P.; He, X. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000, 407, 530-535.
76. Mao, B. Y.; Wu, W.; Li, Y.; Hoppe, D.; Stannek, P.; Glinka, A.; Niehrs, C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001, 411, 321-325.
77. Melki, J. R.; Vincent, P. C.; Brown, R. D.; Clark, S. J. Hypermethylation of E-cadherin in leukemia. Blood 2000, 95, 3208-3213.
78. Sharma, S.; Lichtenstein, A. Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. Blood 2009, 114, 4179-4185.
79. Bafico, A.; Gazit, A.; Pramila, T.; Finch, P. W.; Yaniv, A.; Aaronson, S. A. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J. Biol. Chem. 1999, 274, 16180-16187.
80. Rush, L. J.; Raval, A.; Funchain, P.; Johnson, A. J.; Smith, L.; Lucas, D. M.; Bembea, M.; Liu, T. H.; Heerema, N. A.; Rassenti, L.; Liyanarachchi, S.; Davuluri, R.; Byrd, J. C.; Plass, C. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004, 64, 2424-2433.
81. Liu, T. H.; Raval, A.; Chen, S. S.; Matkovic, J. J.; Byrd, J. C.; Plass, C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res. 2006, 66, 653-658.
82. Chim, C. S.; Pang, R.; Liang, R. Epigenetic dysregulation of the Wnt signalling pathway in chronic lymphocytic leukaemia. J. Clin. Pathol. 2008, 61, 1214-1219.
83. Seeliger, B.; Wilop, S.; Osieka, R.; Galm, O.; Jost, E. CpG island methylation patterns in chronic lymphocytic leukemia. Leuk. Lymphoma 2009, 50, 419-426.
84. Suzuki, H.; Watkins, D. N.; Jair, K. W.; Schuebel, K. E.; Markowitz, S. D.; Chen, W. D.; Pretlow, T. P.; Bin, Y.; Akiyama, Y.; van Engeland, M.; Toyota, M.; Tokino, T.; Hinoda, Y.; Imai, K.; Herman, J. G.; Baylin, S. B. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genetics 2004, 36, 417-422.
85. Kawano, Y.; Kypta, R. Secreted antagonists of the Wnt signalling pathway. J. Cell Science 2003, 116, 2627-2634.
86. Mazieres, J.; He, B.; You, L.; Xu, Z. D.; Lee, A. Y.; Mikami, I.; Reguart, N.; Rosell, R.; McCormick, F.; Jablons, D. M. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004, 64, 4717-4720.
87. Chim, C. S.; Fung, T. K.; Wong, K. F.; Lau, J. S.; Liang, R. Infrequent Wnt inhibitory factor-1 (Wif-1) methylation in chronic lymphocytic leukemia. Leuk. Res. 2006, 30, 1135-1139.
88. Longo, P. G.; Laurenti, L.; Gobessi, S.; Petlickovski, A.; Pelosi, M.; Chiusolo, P.; Sica, S.; Leone, G.; Efremov, D. G. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007, 21, 110-120.
89. Longo, P. G.; Laurenti, L.; Gobessi, S.; Sica, S.; Leone, G.; Efremov, D. G. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111, 846-855.
90. Plate, J. M. D. PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase-8 activation. Leuk. Lymphoma 2004, 45, 1519-1529.
91. Ringshausen, I.; Schneller, F.; Bogner, C.; Hipp, S.; Duyster, J.; Peschel, C.; Decker, T. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B- CLL: association with protein kinase C8. Blood 2002, 100, 3741-3748.
92. Christian, S. L.; Sims, P. V.; Gold, M. R. The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. J. Immunol. 2002, 169, 758-769.
93. Travis, A.; Amsterdam, A.; Belanger, C.; Grosschedl, R. Lef-1, A Gene Encoding A Lymphoid-Specific with Protein, An Hmg Domain, Regulates T-Cell Receptor-Alpha Enhancer Function. Genes Dev. 1991, 5, 880-894.
94. Howe, D.; Bromidge, T. Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma. Leuk. Res. 2006, 30, 29-32.
95. Gutierrez, N. C.; Ocio, E. M.; Rivas, J. D. L.; Maiso, P.; Delgado, M.; Ferminan, E.; Arcos, M. J.; Sanchez, M. L.; Hernandez, J. M.; Miguel, J. F. S. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007, 21, 541-549.
96. Jelinek, D. F.; Tschumper, R. C.; Stolovitzky, G. A.; Iturria, S. J.; Tu, Y. H.; Lepre, J.; Shah, N.; Kay, N. E. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol. Cancer Res.2003, 1, 346-361.
97. Claus, R.; Almstedt, M.; Lubbert, M. Epigenetic treatment of hematopoietic malignancies: In vivo targets of demethylating agents. Semin. Oncol. 2005, 32, 511-520.
98. Kantarjian, H. M.; O'Brien, S.; Huang, X. L.; Garcia-Manero, G.; Ravandi, F.; Cortes, J.; Shan, J. Q.; Davisson, J.; Bueso-Ramos, C. E.; Issa, J. P. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome - Comparison with historical experience. Cancer 2007, 109, 1133-1137.
99. Issa, J. P.; Byrd, J. C. Decitabine in chronic leukemias. Semin. Hematol. 2009, 42, 43-49.
100. Twentyman, P. R.; Lambert, E.; Muller, M.; Rees, J. K. H. Selective toxicity of ethacrynic-acid towards lymphocytes of chronic lymphocytic-leukemia In vitro. Leukemia 1992, 6, 726-728.
101. Jin, G. Y.; Lu, D. S.; Yao, S. Y.; Wu, C. C. N.; Liu, J. X.; Carson, D. A.; Cottam, H. B. Amide derivatives of ethacrynic acid: Synthesis and evaluation as antagonists of Wnt/beta-catenin signaling and CLL cell survival. Bioorg. Med. Chem. Lett. 2009, 19, 606-609.
102. Lepourcelet, M.; Chen, Y. N.; France, D. S.; Wang, H.; Crews, P.; Petersen, F.; Bruseo, C.; Wood, A. W.; Shivdasani, R. A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004, 5, 91-102.
103. Wei, W.; Chua, M. S.; Grepper, S.; So, S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int. J. Cancer 2010, 126, 2426-36.
104. Doghman, M.; Cazareth, J.; Lalli, E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J. Clin. Endocrinol. Metab. 2008, 93, 3222-3225.
105. Minke, K. S.; Staib, P.; Puetter, A.; Gehrke, I.; Gandhirajan, R. K.; Schlosser, A.; Schmitt, E. K.; Hallek, M.; Kreuzer, K. A. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur. J. Haematol. 2009, 82, 165-175.
106. Gandhirajan, R. K.; Staib, P. A.; Minke, K.; Gehrke, I.; Plickert, G.; Schlosser, A.; Schmitt, E. K.; Hallek, M.; Kreuzer, K. A. Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 2010, 12, 326-335.
107. Lu, D. S.; Cottam, H. B.; Corr, M.; Carson, D. A. Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc. Natl. Acad. Sci. USA 2005, 102, 18567-18571.
108. Gardner, S. H.; Hawcroft, G.; Hull, M. A. Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br. J. Cancer 2004,91, 153-163.
109. Robak, P.; Robak, T.; Smolewski, P.; Linke, A.; Cebula, B. Cytotoxic effect of Sdx-308, analogue of R-enantiomer of etodolac, in combination with purine analogues or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Haematologica 2008,93, 219-219.
110. Rigas, B.; Kashfi, K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med. 2004, 10, 324-330.
111. Nath, N.; Kashfi, K.; Chen, J.; Rigas, B. Nitric oxide-donating aspirin inhibits beta-catenin T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proc. Natl. Acad. Sci. USA 2003, 100, 12584-12589.
112. Emami, K. H.; Nguyen, C.; Ma, H.; Kim, D. H.; Jeong, K. W.; Eguchi, M.; Moon, R. T.; Teo, J. L.; Oh, S. W.; Kim, H. Y.; Moon, S. H.; Ha, J. R.; Kahn, M. A small molecule inhibitor of beta- catenin/cyclic AMP response element-binding protein transcription. Proc. Natl. Acad. Sci. USA 2004, 101, 12682-1268.
113. Shustik, C.; Turner, A. R.; Desjardins, P.; Fernandez, L.; Rubin, S.; Larratt, L.; Duncan, A. M. V.; Rizi, D.; Sadura, A.; Shepherd, L.; Li, D.; Rassenti, L.; Kipps, T. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2010, 24, 237-239.
114. Byrd, J. C.; Rai, K.; Peterson, B. L.; Appelbaum, F. R.; Morrison, V. A.; Kolitz, J. E.; Shepherd, L.; Hines, J. D.; Schiffer, C. A.; Larson, R. A. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105, 49-53.
115. Morrell, N. T.; Leucht, P.; Zhao, L. D.; Kim, J. B.; ten Berge, D.; Ponnusamy, K.; Carre, A. L.; Dudek, H.; Zachlederova, M.; McElhaney, M.; Brunton, S.; Gunzner, J.; Callow, M.; Polakis, P.; Costa, M.; Zhang, X. M.; Helms, J. A.; Nusse, R. Liposomal packaging generates Wnt Protein with in vivo biological activity. PLoS One 2008,3, e2930.
116. Chen, M. Y.; Wang, J. B.; Lu, J. Y.; Bond, M. C.; Ren, X. R.; Lyerly, H. K.; Barak, L. S.; Chen, W. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009, 48, 10267-10274.
117. Shan, J. F.; Shi, D. L.; Wang, J. M.; Zheng, J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 2005,44, 15495-15503.
118. Chen, B. Z.; Dodge, M. E.; Tang, W.; Lu, J. M.; Ma, Z. Q.; Fan, C. W.; Wei, S. G.; Hao, W. N.; Kilgore, J.; Williams, N. S.; Roth, M. G.; Amatruda, J. F.; Chen, C.; Lum, L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 2009, 5, 100-107.
119. Park, C. H.; Chang, J. Y.; Hahm, E. R.; Park, S.; Kim, H. K.; Yang, C. H. Quercetin, a potent inhibitor against beta-catenin/Tcf signaling in SW480 colon cancer cells. Biochem. Biophys. Res. Commun. 2005,328, 227-234.
120. Chen, Z. C.; Venkatesan, A. M.; Dehnhardt, C. M.; Dos Santos, O.; os Santos, E.; yral-Kaloustian, S.; Chen, L.; Geng, Y.; Arndt, K. T.; Lucas, J.; Chaudhary, I.; Mansour, T. S. 2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer. Bioorg. Med. Chem. Lett. 2009, 19, 4980-4983.